Search
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalThis drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTalactoferrin alfa
go.drugbank.com/drugs/DB05426InvestigationalIt increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation. … Lactoferrin, a protein found in breast milk is developed by Agennix.
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis … These molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis.
Sodium phosphate, dibasic, unspecified form
go.drugbank.com/drugs/DB14504ApprovedMixtures: Ready-to-Use, Ready-to-Use EnemaEquine Botulinum Neurotoxin A Immune FAB2
go.drugbank.com/drugs/DB13900ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.
Zilpaterol
go.drugbank.com/drugs/DB11479ExperimentalVet approvedZilpaterol is a β2 adrenergic agonist sold under the trade name, Zilmax, produced by Intervet, a subsidiary of Merck & Co. … Zilpaterol is typically fed to cattle in the last three to six weeks of life with a brief washout period to clear the drug from the tissues before slaughter.
NRP409
go.drugbank.com/drugs/DB05235ExperimentalNRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Clonixin
go.drugbank.com/drugs/DB09218InvestigationalClonixin is a non-steroidal anti-inflammatory drug.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSEquine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalMLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.